Cancer Research Aziza Shad  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 4268-4272, October 1, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fong, K. M.
Right arrow Articles by Smith, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fong, K. M.
Right arrow Articles by Smith, P. J.

Loss of Heterozygosity Frequently Affects Chromosome 17q in Non-Small Cell Lung Cancer1

Kwun M. Fong2, Yoshiki Kida, Paul V. Zimmerman, Makoto Ikenaga and Peter J. Smith3

Queensland Cancer Fund Research Unit, Department of Pathology, University of Queensland Medical School, Herston, Queensland, Australia 4006 [K. M. F., Y. K., M. I., P. J. S.] and Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia 4032 [K. M. F., P. V. Z.]

Although the short arm of chromosome 17, which contains the p53 gene, is frequently affected by loss of heterozygosity (LOH) in lung cancer, little is known about similar changes on the long arm. We found that LOH affected one or more of six loci along chromosome 17 in 59% of 102 informative non-small cell lung cancer (NSCLC) cases. Specifically, the frequency of LOH at 17q was 42%, approaching that at 17p (54%), and two distinct 17q regions were implicated. LOH at D17S4 on 17q was more frequent in adenocarcinomas than in squamous cell carcinomas, whereas squamous cell carcinomas had more LOH at 17p than at 17q, findings that indicate molecular genetic heterogeneity between the major NSCLC subtypes. In addition, LOH at 17q correlated with higher T stages and a significantly worse prognosis. In comparison, 25% of cases had mutations of p53 exons 5–8 but these were not associated with stage or survival. The data suggest that independent of p53, there are important tumor suppressor gene(s) on 17q that may influence NSCLC pathogenesis, progression, and survival.

1 This study was supported by TPCH, the Queensland Cancer Fund, and by a NH and MRC (Australia) Medical Postgraduate Scholarship (K. F.).

2 To whom requests for reprints should be addressed.

3 Present address: Department of Hematology and Oncology, Royal Children's Hospital, Flemington Road, Parkville, Victoria, Australia 3052.

Received 7/13/95. Accepted 8/17/95.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
G. Xinarianos, F. E. McRonald, J. M. Risk, N. L. Bowers, G. Nikolaidis, J. K. Field, and T. Liloglou
Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer
Hum. Mol. Genet., July 1, 2006; 15(13): 2038 - 2044.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. E. Larsen, M. L. Colosimo, I. A. Yang, R. Bowman, P. V. Zimmerman, and K. M. Fong
CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung
Carcinogenesis, March 1, 2006; 27(3): 525 - 532.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
F. Cave-Riant, B. Cuillerier, M. Beau-Faller, N. Martinet, F. Alla, C. Bronner, A. Schneider, P. Oudet, and M. P. Gaub
Association of Genetic Defects in Primary Resected Lung Adenocarcinoma Revealed by Targeted Allelic Imbalance Analysis
Am. J. Respir. Cell Mol. Biol., October 1, 2002; 27(4): 495 - 502.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. P. Wong, W. K. Lam, E. Wang, S. W. Chiu, C. L. Lam, and L. P. Chung
Primary Adenocarcinomas of the Lung in Nonsmokers Show a Distinct Pattern of Allelic Imbalance
Cancer Res., August 1, 2002; 62(15): 4464 - 4468.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Miura, E. D. Bowman, R. Simon, A. C. Peng, A. I. Robles, R. T. Jones, T. Katagiri, P. He, H. Mizukami, L. Charboneau, et al.
Laser Capture Microdissection and Microarray Expression Analysis of Lung Adenocarcinoma Reveals Tobacco Smoking- and Prognosis-related Molecular Profiles
Cancer Res., June 1, 2002; 62(11): 3244 - 3250.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Sasatomi, S. D. Finkelstein, J. D. Woods, A. Bakker, P. A. Swalsky, J. D. Luketich, H. C. Fernando, and S. A. Yousem
Comparison of Accumulated Allele Loss between Primary Tumor and Lymph Node Metastasis in Stage II Non-small Cell Lung Carcinoma: Implications for the Timing of Lymph Node Metastasis and Prognostic Value
Cancer Res., May 1, 2002; 62(9): 2681 - 2689.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Zöchbauer-Müller, K. M. Fong, A. K. Virmani, J. Geradts, A. F. Gazdar, and J. D. Minna
Aberrant Promoter Methylation of Multiple Genes in Non-Small Cell Lung Cancers
Cancer Res., January 1, 2001; 61(1): 249 - 255.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi
Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. A. VASSILAKIS, G. SOURVINOS, M. MARKATOS, K. PSATHAKIS, D. A. SPANDIDOS, N. M. SIAFAKAS, and D. BOUROS
Microsatellite DNA Instability and Loss of Heterozygosity in Pulmonary Sarcoidosis
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1729 - 1733.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. Hashimoto, Y. Tokuchi, M. Hayashi, Y. Kobayashi, K. Nishida, S.-i. Hayashi, Y. Ishikawa, S. Tsuchiya, K. Nakagawa, J.-i. Hayashi, et al.
p53 Null Mutations Undetected by Immunohistochemical Staining Predict a Poor Outcome with Early-Stage Non-Small Cell Lung Carcinomas
Cancer Res., November 1, 1999; 59(21): 5572 - 5577.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Toyota, C. Ho, M. Ohe-Toyota, S. B. Baylin, and J.-P. J. Issa
Inactivation of CACNA1G, a T-Type Calcium Channel Gene, by Aberrant Methylation of Its 5' CpG Island in Human Tumors
Cancer Res., September 1, 1999; 59(18): 4535 - 4541.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Geradts, K. M. Fong, P. V. Zimmerman, R. Maynard, and J. D. Minna
Correlation of Abnormal RB, p16ink4a, and p53 Expression with 3p Loss of Heterozygosity, Other Genetic Abnormalities, and Clinical Features in 103 Primary Non-Small Cell Lung Cancers
Clin. Cancer Res., April 1, 1999; 5(4): 791 - 800.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
D A Spandidos, G Sourvinos, H Kiaris, and J Tsamparlakis
Microsatellite instability and loss of heterozygosity in human pterygia
Br J Ophthalmol, June 1, 1997; 81(6): 493 - 496.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.